Patient Safety
Evidence-based strategies and clinical best practices for mitigating nausea, delayed gastric emptying, and other common GI side effects associated with dual-agonist GLP-1/GIP therapy.
Explore the extensive metabolic, cardiovascular, and renal benefits of GLP-1 receptor agonists beyond their well-known weight loss effects.
Analyzing the shift from dual GIP/GLP-1 agonists to triple GIP/GLP-1/Glucagon agonists in metabolic disease treatment.
A deep dive into clinical data on weight regain after stopping GLP-1 therapy, and why structured off-ramps are critical.
A comprehensive clinical comparison between semaglutide and tirzepatide focusing on weight loss efficacy and metabolic benefits.
Addressing the 40% muscle loss danger in generic GLP-1 regimens and how specific, structured protocols are preventing sarcopenia.
An independent review of why 73% of patients experience nutrient deficiencies on GLP-1 medications and the critical role of physician-led protocols.
Board-certified physicians, quarterly labs, muscle-preserving protocols, supplement Rx, and resistance training guidance — all included.
See the Program →